Trial record 2 of 499 for:    lupus

A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Centocor Research & Development, Inc.
ClinicalTrials.gov Identifier:
NCT01702740
First received: July 6, 2012
Last updated: October 5, 2012
Last verified: October 2012
  Purpose

The main purpose of this study was to evaluate the safety and pharmacokinetics (PK, the action of a drug in the body over a period of time) of multiple intravenous (IV) administrations of CNTO 136 in patients with cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE). The secondary goal of this study was to assess the pharmacodynamics (biochemical and physiological effects of a drug and the mechanisms of action), immune response, and clinical response.


Condition Intervention Phase
Lupus Erythematosus, Cutaneous
Lupus Erythematosus, Systemic
Drug: 1 mg/kg CNTO 136
Drug: 4 mg/kg CNTO 136
Drug: 10 mg/kg CNTO 136
Drug: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 1, Double-blind, Placebo-controlled, Multiple Intravenous, Ascending-Dose Study of CNTO 136 to Evaluate Safety and Pharmacokinetics in Subjects With Cutaneous Lupus Erythematosus and to Evaluate Safety and Pharmacokinetics in a Cohort of Subjects With Systemic Lupus Erythematosus

Resource links provided by NLM:


Further study details as provided by Centocor Research & Development, Inc.:

Primary Outcome Measures:
  • Number of participants with adverse events [ Time Frame: Up to 26 weeks ] [ Designated as safety issue: No ]
  • Pharmacokinetic profile of CNTO 136 [ Time Frame: Up to 22 weeks ] [ Designated as safety issue: No ]
    Blood serum concentration over time

  • Physical examinations [ Time Frame: Up to 26 weeks ] [ Designated as safety issue: No ]
    Assessment of head, eyes, ears, nose and throat, skin and neck, lungs, heart, abdomen, extremities, general neurologic status, and oral examination

  • Electrocardiograms (ECGs) [ Time Frame: Up to 26 weeks ] [ Designated as safety issue: No ]
  • Sitting blood pressure [ Time Frame: Up to 26 weeks ] [ Designated as safety issue: No ]
  • Heart rate [ Time Frame: Up to 26 weeks ] [ Designated as safety issue: No ]
  • Respiration rate [ Time Frame: Up to 26 weeks ] [ Designated as safety issue: No ]
  • Oral temperature [ Time Frame: Up to 26 weeks ] [ Designated as safety issue: No ]
  • Hemoglobin [ Time Frame: Up to 26 weeks ] [ Designated as safety issue: No ]
  • Hematocrit [ Time Frame: Up to 26 weeks ] [ Designated as safety issue: No ]
  • Platelets and total white blood cells (WBC) [ Time Frame: Up to 26 weeks ] [ Designated as safety issue: No ]
  • Albumin and total protein [ Time Frame: Up to 26 weeks ] [ Designated as safety issue: No ]
  • Alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) [ Time Frame: Up to 26 weeks ] [ Designated as safety issue: No ]
  • Blood urea nitrogen (BUN), calcium, creatinine, and total bilirubin [ Time Frame: Up to 26 weeks ] [ Designated as safety issue: No ]
  • Chloride, potassium, and sodium [ Time Frame: Up to 26 weeks ] [ Designated as safety issue: No ]
  • Bicarbonate [ Time Frame: Up to 26 weeks ] [ Designated as safety issue: No ]
  • Creatine kinase [ Time Frame: Up to 26 weeks ] [ Designated as safety issue: No ]
  • Gamma-glutamyl-transferase [ Time Frame: Up to 26 weeks ] [ Designated as safety issue: No ]
  • Glucose [ Time Frame: Up to 26 weeks ] [ Designated as safety issue: No ]
  • Lymphocytes and neutrophils [ Time Frame: Up to 26 weeks ] [ Designated as safety issue: No ]
  • Inorganic phosphate [ Time Frame: Up to 26 weeks ] [ Designated as safety issue: No ]
  • Fasting Lipid Panel [ Time Frame: Up to 8 weeks ] [ Designated as safety issue: No ]
    Total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), very low-density lipoprotein (VLDL), and triglycerides.


Secondary Outcome Measures:
  • Pharmacodynamics evaluations [ Time Frame: Up to 22 weeks ] [ Designated as safety issue: No ]
    Percentage change from baseline in serum and plasma biomarker data

  • Immune response [ Time Frame: Up to 22 weeks ] [ Designated as safety issue: No ]
    The formation of antibodies to CNTO 136

  • Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) [ Time Frame: Up to 22 weeks ] [ Designated as safety issue: No ]
    Measurement of disease activity, scored from 0 (absent) to 70 (severe), and damage, scored from 0 (absent) to 56 (severe)

  • British Isles Lupus Assessment Group (BILAG) score [ Time Frame: Up to 22 weeks ] [ Designated as safety issue: No ]
    Measures the need for alterations or intensification of therapy. The assessing physician considers each item as to its presence in the past month, and answers 0 = not present, 1 = improving; 2 = same; 3 = worse; or 4 = new.

  • SELENA-SLEDAI Flare Composite [ Time Frame: Up to 22 weeks ] [ Designated as safety issue: No ]
    Assesses the presence and severity of lupus flare. Scores range from 0 (mild) to 105 (severe).


Enrollment: 49
Study Start Date: March 2007
Study Completion Date: October 2009
Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Part A, 1 mg/kg CNTO 136 Drug: 1 mg/kg CNTO 136
Type=exact number, unit=mg, number=1, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
Experimental: Part A, 4 mg/kg CNTO 136 Drug: 4 mg/kg CNTO 136
Type=exact number, unit=mg, number=4, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
Experimental: Part A, 10 mg/kg CNTO 136 Drug: 10 mg/kg CNTO 136
Type=exact number, unit=mg, number=10, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
Experimental: Part B, 10 mg/kg CNTO 136/placebo Drug: 10 mg/kg CNTO 136
Type=exact number, unit=mg, number=10, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
Drug: Placebo
Form=liquid for infusion, route=intravenous use, every 2 weeks for 6 weeks.

Detailed Description:

In Part A of this study, patients with CLE were randomly assigned (like flipping a coin) to receive multiple IV doses of CNTO 136, a human anti-IL 6 monoclonal antibody (an immune protein that binds to interleukin 6) or placebo (a substance that appears identical to the treatment and has no active ingredients). Patients and study personnel did not know the identity of the administered treatments (double-blind study). Increasing doses were given, based on safety data collected during the initial weeks of treatment. In Part B, which was also double-blind, patients with SLE were randomly assigned to receive multiple IV doses of the highest well-tolerated dose, as determined in Part A, of CNTO 136, or placebo.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of cutaneous lupus erythematosus (CLE, including subacute cutaneous lupus erythematosus, discoid lupus erythematosus, or lupus erythematosus tumidus) or systemic lupus erythematosus (SLE)

    • Had a body weight less than or equal to 100 kg
    • Patients in Part A who were taking systemic medications for CLE had to be on a stable dose for 4 weeks before the first study agent infusion
    • Patients in Part B taking systemic medications for SLE had to be on a stable dose for at least 3 months before the first study agent infusion
    • Given informed consent and willing and able to adhere to the study visit schedule and other protocol requirements; agreed to avoid alcohol intake; and took adequate measures to prevent pregnancy

Exclusion Criteria:

  • Significant history of or concurrent medical condition (other than lupus)
  • Use of specific previous or concurrent medications or investigational therapies
  • Known or suspected allergy to the study agent or it constituents, having recently donated blood, or having any significant laboratory test values requiring intervention
  • Patients with SLE in Part B could not have active central nervous system lupus
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01702740

Sponsors and Collaborators
Centocor Research & Development, Inc.
Investigators
Study Director: Centocor Research & Development, Inc., PA, USA Clinical Trial Centocor Research & Development, Inc.
  More Information

No publications provided by Centocor Research & Development, Inc.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Centocor Research & Development, Inc.
ClinicalTrials.gov Identifier: NCT01702740     History of Changes
Other Study ID Numbers: CR013000, C0136T03, 2006-002432-25
Study First Received: July 6, 2012
Last Updated: October 5, 2012
Health Authority: Sweden: Medical Products Agency

Keywords provided by Centocor Research & Development, Inc.:
Cutaneous lupus erythematosus
Systemic lupus erythematosus
Lupus erythematosus
Human anti-IL 6 monoclonal antibody
Sirukumab

Additional relevant MeSH terms:
Lupus Erythematosus, Cutaneous
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Skin Diseases
Autoimmune Diseases
Immune System Diseases

ClinicalTrials.gov processed this record on August 28, 2014